

South Carolina  
**Department of Health and Human Services**  
Post Office Box 8206  
Columbia, South Carolina 29202-8206

**Pharmacy and Therapeutics (P&T) Committee Meeting**  
**August 2, 2023**  
MINUTES

**1. Call to Order**

A meeting of the P&T Committee convened at 4:00 p.m. on Wednesday, August 2, 2023.

**2. Welcome**

Edward Behling, MD, called the meeting to order and welcomed members, guests, and staff members.

Dr. Behling opened the meeting by stating that the P&T Committee meetings are held in compliance with the Freedom of Information Act's (FOIA) mandate that the public is notified when the public's business is being done, and that furthermore, the public has been notified that this facility is accessible to individuals with disabilities, and special accommodations could have been provided if requested in advance.

**3. Committee Members Present:**

Divya Ahuja, MD  
Kimberly Rudd, MD  
Cheryl Hartvigsen, RPh  
Erika Tillery, PharmD

Edward Behling, MD  
Jony Bolinger, MD  
Thomas Phillips, RPh  
Patricia Witherspoon, MD

Duncan Norton, MD  
Phillip Mubarak, MD

**SC DHHS Staff:**

Cheryl Anderson BS, RPh  
Kevin Wessinger, MD  
Kim Bristow, RPh  
Brandie Crider  
Ashley Sirianni, DNP, FNP-BC

**Magellan Medicaid Admin:**

Lisa Correll, PharmD  
Lori Ash

**4. Discussion Topics**

**A. Committee Meeting Minutes, Wednesday, May 3, 2023**

The draft minutes from the previous P&T Committee meeting were emailed to the members so that they could review the document prior to the meeting. The minutes were approved unanimously.

**B. Public Comment**

Company	Speaker	Drug/Class
Axsome	Sucharita Somkuwar, PhD	Auvelity® (Antidepressants, Other)

**C. Drug Classes for Review**

*Classes for Review*

Lipotropics, Other: Omega-3 Fatty Acids

*Classes for Re-review*

Antidepressants, Other: Oral formulations

Proton Pump Inhibitors

The chart below represents the recommendations from the P & T Committee:

<b>LIPOTROPICS, OTHER: OMEGA-3 FATTY ACIDS</b>	
Preferred	Non-Preferred
Vascepa®‡	Icosapent ethyl
Omega 3 acid ethyl esters caps‡	Lovaza®
	Omega 3 OTC
<i>Class level PA in effect for indication: hypertriglyceridemia TG≥500mg/dL</i>	
<b>ANTIPRESSANTS, OTHER: ORAL FORMULATIONS</b>	
Preferred	Non-Preferred
Bupropion (SR and XL 150 and 300mg)	Aplenzin™
Devenlafaxine succinate ER‡ (25,50, 100mg tabs)	Auvelity™
Mirtazapine tabs/ODT	Desvenlafaxine ER base
Nefazodone tabs	Drizalma Sprinkle™
Phenelzine tabs	Effexor XR® tabs
Trazodone tabs	Fetzima®
Venlafaxine tabs/ER cap	Forfivo XL®
Viibryd®‡ (10, 20, 40mg tabs)	Marplan®
	Pristiq®
	Remeron®, Remeron® SolTab
	Trintellix®
	Venlafaxine besylate ER
	Vilazodone
	Wellbutrin®, SR, XL

PROTON PUMP INHIBITORS	
Preferred	Non-Preferred
Omeprazole	Aciphex®
Dexilant®‡ caps	Dexlansoprazole
Nexium® (for oral suspension)	Esomeprazole
Pantoprazole	Prevacid® capsules/solutab
Protonix®‡ granules (for oral suspension)	Prilosec® suspension
	Protonix®
	Zegerid®

- ‡ Added as “Preferred”
- + Moved to “Non-Preferred”

**5. Old Business**

None

**6. New Business**

Dr. Wessinger, Chief Medical Officer, shared the agency’s plan to add the OmniPod® 5 insulin pump to the Diabetic Supply (DSP) list effective October 1, 2023 to better serve the needs of pediatric patients. The P&T Committee voted to add this insulin pump to the DSP list.

Lisa Correll presented new drugs to market and shared the cadence of PDL updates which occur every January and July. Pharma meetings are offered for 1 entity per year and remain virtual.

**7. Resolved Items**

*Classes for Review*

Lipotropics, Other: Omega-3 Fatty Acids

*Classes for Re-review*

Antidepressants, Other: Oral formulations

Proton Pump Inhibitors

**8. Closing Comments**

The next meeting will be held Wednesday, November 2, 2023.

**9. Adjournment**

The meeting adjourned at 4:49 p.m.